<DOC>
	<DOCNO>NCT01656161</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy triptorelin embonate 22.5 mg 6-month formulation administer subcutaneous ( skin ) route : - achieve castrate level testosterone ( &lt; 1.735 nmol/L ) Day 29 [ i.e. , 28 day investigational medicinal product ( IMP ) injection ] , - maintain serum testosterone castrate level Month 2 ( Day 57 ) end Month 12 ( Day 337 ) participant advanced prostate cancer .</brief_summary>
	<brief_title>Study Efficacy , Pharmacokinetics , Safety Two Subcutaneous Injections Triptorelin Embonate 6 Month Formulation Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Summary Meets protocolspecified criterion qualification contraception Is willing able remain confine study unit entire duration treatment period comply restriction relate food , drink medication Voluntarily consent participate provide write informed consent prior protocolspecific procedure Summary Has history current use overthecounter medication , dietary supplement , drug ( include nicotine alcohol ) outside protocolspecified parameter Has sign , symptom history condition , per protocol opinion investigator , might compromise : 1 ) safety wellbeing participant study staff ; 2 ) safety wellbeing participant 's offspring ( pregnancy breastfeed ) ; 3 ) analysis result</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>